Back to Journals » OncoTargets and Therapy » Volume 13

Silencing of Long Non-Coding RNA-HCG18 Inhibits the Tumorigenesis of Gastric Cancer Through Blocking PI3K/Akt Pathway [Retraction]

Authors Ma F , An K, Li Y

Received 20 November 2020

Accepted for publication 20 November 2020

Published 26 November 2020 Volume 2020:13 Pages 12195—12196

DOI https://doi.org/10.2147/OTT.S293126



Ma F, An K, Li Y. Onco Targets Ther. 2020;13:2225–2234.


The Editor and Publisher of OncoTargets and Therapy wish to retract the published paper.


The journal was notified of possible image manipulation and duplication in:

● Figure 2D - panels MGC803 Blank, si-NC, si-HCG18 and panels AGS Blank, si-NC, si-HCG18, which all appeared to share duplicated elements
● Figure 3A - panels AGS 0 h si-NC and 48 h Blank, which appeared to show duplicated elements shared between both images
● Figure 5C - panels PI si-NC, si-HCG18 and si-HCG18+740-P
● Figure 6A - panels Mock 4 w, si-HCG18 2 w and si-HCG18 4 w, which appeared to show image splicing and irregular shadowing


The authors were unable to provide the necessary raw data for their study and the editor determined the findings of the study were no longer valid.


Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.


The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

This retraction relates to this paper

Creative Commons License © 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.